Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price lifted by Truist Financial from $30.00 to $36.00 in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

CPRX has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $30.50.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock traded up $0.11 during trading on Monday, hitting $23.56. The company had a trading volume of 177,267 shares, compared to its average volume of 1,190,443. The firm has a market capitalization of $2.81 billion, a P/E ratio of 19.87, a price-to-earnings-growth ratio of 3.82 and a beta of 0.75. Catalyst Pharmaceuticals has a one year low of $12.43 and a one year high of $24.27. The stock’s 50-day moving average price is $20.81 and its 200 day moving average price is $18.17.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CPRX. Pacer Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after acquiring an additional 2,965,310 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after purchasing an additional 1,587,794 shares during the period. Vanguard Group Inc. boosted its position in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after purchasing an additional 860,244 shares in the last quarter. Kennedy Capital Management LLC grew its stake in shares of Catalyst Pharmaceuticals by 101.1% in the 1st quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company’s stock valued at $16,924,000 after buying an additional 533,802 shares during the period. Finally, Renaissance Technologies LLC increased its position in Catalyst Pharmaceuticals by 15.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.